Senate Gene Editing Hearing: Trust In US FDA On Display
Discussion on cutting edge medical technology demonstrates the strong reputation FDA has built as a regulator. Witnesses in the gene editing field said FDA is doing a good job – and Congress is likely to leave it at that.
You may also be interested in...
Gene Editing: A Powerful, Growing Modality In Regenerative Medicine
Regenerative medicine has made advances in recent years to emerge as one of the key fields with a chance of addressing, and even curing, diseases that until now had few or no treatment options.
Drug Pricing Reforms In US Congress: Legacy Systems vs. Cutting-Edge
A House hearing on bipartisan drug pricing reform bills continues the intense focus on the role of pharmacy benefit managers. But it also shows continued interest in finding ways to make payment systems work for cutting edge gene therapies.
FDA Opioid Review Adds Another Push For Advisory Committee Overhaul
External report on the US FDA’s response to the opioid epidemic includes detailed recommendations for enhancements to the advisory committee review process. That dovetails with the agency’s ongoing look at how best to use the expert panels.